Johnny Cai, DO
Hematology/Oncology · Fremont
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 10
- 2 carriers
- Offices
- 3
Offices
3 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Washington Hospital. That is not proof they admit you there this week.
Plans that list them
10 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Cai’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
10 of 10 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Washington HospitalFremont, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Washington Hospital Healthcare SystemPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.188, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.164, Oct 2024 – Sep 2025
See every measure and the patient survey for Washington Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 6 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.188 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.164 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.88) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.92 (0.59 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.95 (139.54 to 246.36) · 48 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 27 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.4 · 164 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.1 · 199 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 463 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 661 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 174 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 2,550 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.35) · 6,970 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,108 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.82 (1.73 to 5.91) · 1,370 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.52 (0 to 3.17) · 589 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.75 (0.25 to 3.25) · 1,315 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.19 (5.83 to 20.56) · 600 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.91 (1.04 to 8.78) · 550 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.17 to 3.14) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 6,079 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 114 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.367 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.8 · 186 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 480 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 33.9 · 186 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 26.5 · 553 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 36.8 · 648 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 590 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.7 (3.2 to 6.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.5 to 14.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 130 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.1 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 202 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.7 (10.2 to 18.5) · 78 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 974 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$32,353
Medicare paid this office $32,353 for 52 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 11 | $3,590 | $171 |
| New patient visit (60+ min) | 15 | $3,098 | $207 |
| New patient visit (45+ min) | 17 | $2,675 | $157 |
Who their Medicare patients are
52 Original Medicare patients in 2024. Average age 76 · Women 67% · Health risk score 1.12. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 71% · Cancer 31% · Diabetes 25% · Coronary heart disease 25% · Chronic kidney disease 25%.
The office billed $103,147, Medicare allowed $40,550 and paid $32,353; for 3,379 services of 33 kinds; $19,650 of it was for drugs given in the office and $12,703 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Drugs they prescribed that Part D paid
$483,489
Pharmacies billed $483,489 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
101 generic and 34 brand-name prescriptions · $483,489 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Hydroxyurea | 11 | $278 | $25 |
Year by year
| 2024 | 135 | 35 | None | 25% | $483,489 |
| 2023 | 143 | 28 | None | None | $437,595 |
| 2022 | 107 | 27 | None | None | $180,946 |
| 2021 | 305 | 43 | None | 16% | $39,183 |
| 2020 | 417 | 65 | 4% (16) | None | $27,647 |
| 2019 | 200 | 40 | None | None | $10,034 |
| 2018 | 34 | None | None | None | $2,993 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Kisqali | 11 | $102,911 | $9,356 |
| Dexamethasone | 13 | $127 | $10 |
2022: 1 drug
| Prednisone | 16 | $117 | $7 |
2021: 5 drugs
| Gabapentin | 23 | $749 | $33 |
| Losartan | 23 | $312 | $14 |
| Atorvastatin | 31 | $270 | $9 |
| Amlodipine Besylate | 31 | $85 | $3 |
| Omeprazole | 16 | $66 | $4 |
2020: 10 drugs
| Gabapentin | 19 | $1,027 | $54 |
| Diclofenac | 16 | $492 | $31 |
| Tamsulosin | 21 | $278 | $13 |
| Fluticasone Propionate | 14 | $270 | $19 |
| Losartan | 19 | $248 | $13 |
| Atorvastatin | 25 | $244 | $10 |
| Alendronate | 13 | $91 | $7 |
| Amlodipine Besylate | 35 | $90 | $3 |
| Rosuvastatin | 17 | $88 | $5 |
| Omeprazole | 14 | $52 | $4 |
2019: 4 drugs
| Diclofenac | 12 | $416 | $35 |
| Losartan | 12 | $205 | $17 |
| Levothyroxine | 13 | $200 | $15 |
| Atorvastatin | 11 | $119 | $11 |
Money from drug and device companies
$365 in 2025
| 2025 | 11 | 15 | None | $365 |
| 2024 | 5 | 7 | None | $244 |
| 2023 | 10 | 16 | None | $464 |
| 2022 | 2 | 4 | None | $96 |
| 2021 | 2 | 2 | None | $116 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Takeda Pharmaceuticals U.S.A. | Iclusig | $93 | 4 payments
|
| Daiichi Sankyo | Enhertu | $49 | 2 payments
|
| Abbvie | Epkinly | $34 | 1 payment
|
| Pfizer | Padcev | $33 | 1 payment
|
| Celgene | None | $28 | 1 payment
|
| Astellas Pharma US | Vyloy | $26 | 1 payment
|
See all 15 published payments
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-12-04 | Iclusig | $22 |
| GlaxoSmithKline | Meals · 2025-11-12 | Ojjaara | $18 |
| Abbvie | Meals · 2025-09-23 | Epkinly | $34 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-09-18 | Iclusig | $20 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-08-20 | Iclusig | $28 |
| Daiichi Sankyo | Meals · 2025-07-25 | Enhertu | $20 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-25 | Lynparza | $14 |
| Pfizer | Meals · 2025-06-11 | Padcev | $33 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-08 | Opdivo | $20 |
| Daiichi Sankyo | Meals · 2025-05-01 | Enhertu | $28 |
| Eisai | Meals · 2025-04-02 | Lenvima | $26 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-20 | Iclusig | $24 |
| Janssen Biotech | Meals · 2025-02-26 | Rybrevant | $23 |
| Celgene | Meals · 2025-02-12 | None | $28 |
| Astellas Pharma US | Meals · 2025-01-30 | Vyloy | $26 |
See earlier years (2024, 2023, 2022, 2021)
2024: $244
| Pfizer | Tukysa | $148 | 3 payments
|
| Teleflex | Arrow | $29 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $26 | 1 payment
|
| Astellas Pharma US | Xospata | $25 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $15 | 1 payment
|
2023: $464
| Astellas Pharma US | Xospata | $119 | 2 payments
|
| Seagen | Adcetris | $75 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $64 | 3 payments
|
| Celgene | Pomalyst | $56 | 2 payments
|
| Karyopharm Therapeutics | Xpovio | $34 | 1 payment
|
| ImmunoGen | Elahere | $29 | 1 payment
|
| Genzyme | Sarclisa | $26 | 1 payment
|
| Incyte | Jakafi | $23 | 1 payment
|
| Mirati Therapeutics | Krazati | $20 | 1 payment
|
| Alexion Pharmaceuticals | None | $19 | 1 payment
|
2022: $96
| Celgene | Pomalyst | $75 | 3 payments
|
| Seagen | Adcetris | $21 | 1 payment
|
2021: $116
| Incyte | Jakafi | $103 | 1 payment
|
| Seagen | Adcetris | $13 | 1 payment
|
Professional record
- NPI
- 1861998452
- Licence
- CA 20A19125
- Trained
- Touro Un College of Osteopathic Medicine, Vallejo, 2018
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2018-04-03
- NPI last updated
- 2024-08-28
- NPI record certified
- 2024-08-28
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 3181 Sw Sam Jackson Park Rd, Portland, OR, 97239 · 14445 Olive View Drive, Sylmar, CA, 91342